Aleos Capital, an independent Spanish asset manager, has announced the first closing of its debut fund, ALEOS FUND I, after securing investment commitments exceeding €150 million. This milestone achieves the fund’s initial target size in less than a year of fundraising, in a challenging market environment, underscoring the strength of the project and the confidence of the investor community.
Sector leadership and top-tier team
The firm is led by two prominent figures in the Spanish healthcare and private equity sectors: Héctor Ciria, former CEO of Quirónsalud and y ex Principal at Apax Partners, and David Santos, former partner at Alantra Private Equity. They are joined by Daniel Aymerich, former head of ICG in Spain and Portugal, forming a six-member team with extensive operational and investment experience.
Investment strategy and value creation
ALEOS FUND I specializes in the biosciences sector, focusing on three strategic verticals: Health & Wellness, Sustainable Nutrition, and Climate & Environment. The fund’s objectives include:
The management company will act as an operating partner for its portfolio companies, leveraging international expansion, sector consolidation (buy-and-build), strengthening of management teams, sustainability, and technology as key levers to generate returns.
Commitment to sustainability and final closing
According to the prospectus filed with the CNMV, the fund is classified under Article 8 of the SFDR Disclosure Regulation, integrating environmental, social, and governance (ESG) criteria throughout its investment process.
The investor base is highly diversified, composed of institutional investors and family offices, with a significant commitment from the management team itself. No single investor currently exceeds 25% of total commitments. Following this successful first closing, Aleos Capital maintains a hard cap of €240 million, with a second and final closing expected by the end of the year.
Before this date, the firm plans to complete its first investment in a high-growth biosciences company, initiating active deployment of the fund’s portfolio.
About Aleos Capital
ALEOS CAPITAL, S.G.E.I.C., S.A. (CNMV registry no. 234) is an institutional private equity firm focused on the lower mid-market in Iberia, specializing in the biosciences sector. The firm targets three key verticals: Health & Wellness, Sustainable Nutrition, and Climate & Environment.
Aleos Capital partners with profitable SMEs to accelerate growth and build sustainable market leaders through a comprehensive operational program, with technology at the core.
The founding team brings extensive private equity and managerial experience, with a proven track record in sourcing opportunities, scaling companies, and executing successful exits
cloud technology axon
Xcalibur Smart Mapping, recognised as the global leader in airborne...
